. "Tamoxifen is a nonsteroidal agent that binds to estrogen receptors (ER), inducing a conformational change in the receptor. This results in a blockage or change in the expression of estrogen dependent genes. The prolonged binding of tamoxifen to the nuclear chromatin of these results in reduced DNA polymerase activity, impaired thymidine utilization, blockade of estradiol uptake, and decreased estrogen response. It is likely that tamoxifen interacts with other coactivators or corepressors in the tissue and binds with different estrogen receptors, ER-alpha or ER-beta, producing both estrogenic and antiestrogenic effects."@en . . "Tamone"@en . "Noltam"@en . "Citofen"@en . . . . . . . . . . . . . . . . "# Jordan VC: Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol. 2006 Jan;147 Suppl 1:S269-76. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16402113 # Jordan VC: Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol. 1993 Oct;110(2):507-17. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8242225 # Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005 Jan 1-7;365(9453):60-2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15639680 # Steiner AZ, Terplan M, Paulson RJ: Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum Reprod. 2005 Jun;20(6):1511-5. Epub 2005 Apr 21. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15845599 # van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG: Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med. 2006 Jan 17;144(2):101-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16418409 # FDA label "@en . "One of the selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the endometrium. [PubChem]"@en . "Chengjian Mao, \"Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells.\" U.S. Patent US20030199022, issued October 23, 2003."@en . . . . . . . "10540-29-1"@en . "Nourytam"@en . "Istubol"@en . . . . . . . . . "(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine"@en . . . . . . . . . . . . . "Tamoxifeno"@en . . . . . "approved"@en . "Tamoxifen"@en . . . "Valodex"@en . . . . . "When a single oral dose of 20 mg is given, the average peak plasma concentration (Cmax) is 40 ng/mL which occurred approximately 5 hours after dosing (Tmax). The Cmax of N-desmethyl tamoxifen is 15 ng/mL. Steady-state concentrations for tamoxifen is achieved in 4 weeks, while steady-state concentrations for N-desmethyl tamoxifen is achieved in 8 weeks. "@en . . "Apo-tamox"@en . . . "Tamoxifene"@en . . . . . . . . "1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene"@en . . . "1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene"@en . . . "65% of the dose was excreted from the body over 2 weeks in which fecal excretion was the primary route of elimination. Tamoxifen is excreted mainly as polar conjugates, with unchanged drug and unconjugated metabolites accounting for less than 30% of the total fecal radioactivity. "@en . . . . . . "Zemide"@en . . . "Diemon"@en . "Humans and other mammals"@en . . . . . . . . . "(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine"@en . " "@en . . "Tamoxifen is indicated for the treatment of metastatic breast cancer in women and men and ductal carcinoma in Situ. "@en . " "@en . . "Tamofen"@en . . . . . "Tamoxifenum"@en . . . "Retaxim"@en . . . . "The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days. "@en . . . "Gen-tamoxifen"@en . "Crisafeno"@en . . . "Tamoxasta"@en . "trans-Tamoxifen"@en . . . "Signs observed at the highest doses following studies to determine LD₅₀ in animals were respiratory difficulties and convulsions."@en . "Oncomox"@en . "Clearance (CL/F) as body weight adjusted in female pediatric patients was approximately 2.3-fold higher than in female breast cancer patients. "@en . "Tamoxifen"@en . "Tamoxif\u00E8ne"@en .